Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. (PFE) is a global biopharmaceutical leader driving innovations in vaccine development and therapeutic treatments. This news hub provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and market strategies.
Access official press releases, earnings reports, and analysis of Pfizer's clinical trial progress. Our curated collection covers FDA approvals, partnership announcements, and research breakthroughs across oncology, immunology, and infectious disease portfolios.
Key updates include quarterly financial results, manufacturing expansions, and strategic collaborations shaping the pharmaceutical landscape. Bookmark this page for reliable insights into one of healthcare's most influential companies, with content organized for efficient navigation across devices.
ViiV Healthcare announced positive results from two phase IIa studies of investigational HIV therapies at CROI 2025. The studies focused on VH4524184 (VH184), a third-generation integrase inhibitor, and VH4011499 (VH499), a capsid inhibitor, both showing promise as long-acting injectable treatments.
VH184 demonstrated significant antiviral activity across three doses (10mg, 50mg, 300mg) in 22 treatment-naive adults. The 300mg dose achieved the maximum viral load decline of -2.69 log10 copies/mL. All side effects were mild to moderate with no serious adverse events.
VH499 showed positive results in 23 treatment-naive adults across doses of 25mg, 100mg, and 250mg. The highest dose (250mg) achieved a -2.2 log10 copies/mL decrease in HIV-1 viral load. The treatment was well-tolerated with only mild to moderate adverse events reported.
FoRx Therapeutics has appointed Dr. Jens Würthner as Chief Medical Officer, bringing over 20 years of clinical development expertise in oncology therapeutics. Dr. Würthner's experience includes successful drug development at companies like Novartis, GlaxoSmithKline, AstraZeneca, and ADC Therapeutics, where he oversaw the development of loncastuximab teserine (Zynlonta).
The company also provided an update on FORX-428, their lead development candidate targeting solid tumors. This PARG (Poly(ADP-ribose) glycohydrolase) inhibitor is progressing toward IND submission by mid-2025. Recent developments include:
- Completion of GLP toxicological testing
- Identification of predictive biomarkers for patient selection
- Promising animal studies showing strong anti-tumor efficacy and good tolerability
Akeso announced that its partner Summit Therapeutics (NASDAQ: SMMT) has entered a clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to accelerate development of potentially landscape-changing combinations to improve standards of care for cancer patients with serious unmet needs. Each study will evaluate ivonescimab plus one of Pfizer's vedotin ADCs in distinct solid tumor settings to determine safety profiles and potential anti-tumor activity.
Under the agreement, Summit will provide ivonescimab while Pfizer will conduct the studies, with oversight from both companies. Both parties retain rights to their respective products. The studies are planned to begin in mid-2025, with further details to be announced later.
Pfizer (NYSE: PFE) has announced a public webcast featuring a discussion with Albert Bourla, Chairman and CEO, at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 10:30 a.m. EST.
The webcast will be accessible through www.pfizer.com/investors, with registration details available immediately. A transcript and replay will be posted within 24 hours after the live discussion and remain accessible for at least 90 days.
The discussion may include forward-looking statements about Pfizer's operating performance, product pipeline, business strategy, COVID-19 response, and ESG priorities. These statements are subject to risks and uncertainties as detailed in Pfizer's Annual Report on Form 10-K and subsequent SEC filings.
Summit Therapeutics (NASDAQ: SMMT) has announced a clinical trial collaboration with Pfizer (NYSE: PFE) to evaluate ivonescimab, a novel PD-1/VEGF bispecific antibody, in combination with Pfizer's antibody drug conjugates (ADCs) across multiple solid tumor settings.
The collaboration aims to assess ivonescimab with several of Pfizer's vedotin-based ADCs in distinct solid tumor settings to determine safety profiles and potential anti-tumor activity. Summit will provide ivonescimab while Pfizer will conduct the studies, with both companies overseeing the trials. Both parties maintain their respective product rights.
The clinical trials are scheduled to begin in mid-2024, with further details to be announced later. The partnership focuses on developing novel mechanisms beyond current available treatments, particularly targeting non-small cell lung cancer and other solid tumors.
Pfizer (NYSE: PFE) announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® in combination with XTANDI® for metastatic castration-resistant prostate cancer (mCRPC). The study showed significant improvement in overall survival across two patient cohorts:
In unselected patients (Cohort 1), the combination therapy achieved a median overall survival of 45.8 months versus 37.0 months with XTANDI and placebo, representing a 20% reduction in death risk and nearly 9-month survival gain. In HRR-mutated patients (Cohort 2), median overall survival was 45.1 months versus 31.1 months with XTANDI and placebo, showing a 38% reduction in death risk and 14-month survival improvement.
The safety profile aligned with known characteristics of both medicines, with common adverse events including anemia, neutropenia, and fatigue. The data has been shared with FDA, EMA, and other global health authorities for potential label updates.
Pfizer (NYSE: PFE) has received FDA approval for ADCETRIS® combination therapy for treating relapsed/refractory large B-cell lymphoma (LBCL). The approval is based on the Phase 3 ECHELON-3 trial results, which showed the ADCETRIS regimen reduced death risk by 37% compared to standard treatment.
The therapy is specifically approved for adult patients with LBCL who have undergone two or more lines of systemic therapy and are not eligible for stem cell transplantation or CAR-T therapy. This marks ADCETRIS's eighth FDA-approved indication.
The ECHELON-3 study demonstrated significant improvement in overall survival, with benefits consistent across CD30 expression levels. More than 3,500 patients annually in the U.S. experience treatment failure after two prior therapy lines for this aggressive form of non-Hodgkin lymphoma.
Pfizer (PFE) and Astellas announced extended follow-up results from their Phase 3 EV-302 trial, evaluating PADCEV® plus KEYTRUDA® in first-line treatment of locally advanced or metastatic urothelial cancer. After 29.1 months of median follow-up, the combination therapy showed significant improvements over chemotherapy:
- Reduced death risk by 49% (HR = 0.51)
- Median overall survival: 33.8 months vs 15.9 months for chemotherapy
- Reduced disease progression risk by 52% (HR = 0.48)
- Median progression-free survival: 12.5 months vs 6.3 months for chemotherapy
The confirmed objective response rate was 67.5% for the combination vs 44.2% for chemotherapy, with complete response rates of 30.4% vs 14.5% respectively. The safety profile remained consistent with previous findings, with no new concerns identified.
Pfizer (PFE) reported strong financial results for full-year 2024, with revenues of $63.6 billion, showing 7% year-over-year operational growth. Excluding Paxlovid and Comirnaty contributions, revenues grew 12% operationally.
Fourth-quarter 2024 revenues reached $17.8 billion, with 21% operational growth excluding COVID products. The company reported full-year 2024 adjusted diluted EPS of $3.11 and fourth-quarter adjusted diluted EPS of $0.63.
Pfizer reaffirmed its 2025 financial guidance, projecting revenues between $61.0 to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00. The company is on track to deliver overall net cost savings of approximately $4.5 billion by end of 2025 from its ongoing cost realignment program.
Pfizer (PFE) announced positive topline results from the Phase 3 BREAKWATER study of BRAFTOVI® combination therapy for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The study demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy.
The BRAFTOVI combination regimen, which includes cetuximab and mFOLFOX6, received accelerated FDA approval in December 2024 for treatment-naïve patients based on improved objective response rate (ORR). The safety profile remained consistent with known profiles of each agent, with no new safety signals identified.
These results will be shared with the FDA to support potential conversion to full approval and with other global regulatory authorities for additional license applications.
FAQ
What is the current stock price of Pfizer (PFE)?
What is the market cap of Pfizer (PFE)?
